14th World Bispecific Summit

Going head to head with Cell Therapy, Bispecific antibody treatments have never been more promising, with the last year seeing more and more assets moving through the clinic, gaining regulatory approval and expanding to treat a wider range of indications.

The World Bispecific Summit returns for its 14^th year with an enriched program boasting comprehensive coverage of all the key discovery, pre-clinical and clinical challenges including design, clinical, regulatory and combination strategies. Led by the industries brightest minds from the likes of Sanofi, Regeneron, the FDA, Alligator Biosciences and Amgen, it’s the perfect platform to celebrate wins, work through challenges and establish connections with the leading pharma, biotech and academic KOLs.

Deep dive into novel target selection, immune cell modulators, target selection and pre-clinical/clinical readouts and gain holistic insight of the current state-of-play in the bispecific landscape to  supercharge your own pipeline from discovery through to IND approval.